Treatment of kidney condition requires an individualisedMay 15, 2007Good patient information is essential for choosing the best treatment for the kidney disease lupus nephritis. Dutch researcher Cecile Grootscholten concludes this following her doctoral research into two methods for treating lupus nephritis. She did not demonstrate any major differences but both treatments have pros and cons. The severity of the kidney disease lupus nephritis varies and the side effects of the treatments differ as well. Therefore Grootscholten advises doctors to thoroughly inform patients in advance about the pros and cons of both treatments. Based on his/her own situation every patient can make a well-considered choice for one of the two treatments. Grootscholten treated two groups of patients for two years with either drips containing cyclophosphamide (treatment 1) or a combination of drips containing prednisone and oral azathioprine (treatment 2). After 2 years all of the patients were further treated with a low dose of oral prednisone and azathioprine. Kidney function The majority of patients faired better than the researchers had expected at the start of the study in 1995. Grootscholten observed that the chance of the disease recurring in the kidneys was greater in the group of patients treated with treatment 2. Shingles also occurred more frequently in this group. However, Grootscholten could not demonstrate a difference between treatment 1 and treatment 2 in terms of long-term kidney function. Moreover in the end, just as many people needed dialysis. Quality of life Treatment 1 was experienced as heavier than treatment 2. Yet there were no differences in terms of quality of life or complaints. Treatment 1 is known to increase the risk of infertility and early menopause. Therefore treatment 2 remains as an alternative. A more extensive study is needed for more concrete statements. Lupus nephritis Lupus nephritis is a severe kidney inflammation caused by the autoimmune disease systemic lupus erythematodes. The body produces antibodies against its own organs and treatment is absolutely necessary. The condition is rare. Each year 6 in every 100,000 people in the Netherlands develop the disease. Up until 40 years ago patients died from lupus nephritis. Since then various treatment methods have been sought to suppress the inflammation in the kidney. To date no thorough research into the differences between these methods had been carried out. Netherlands Organisation for Scientific Research |
|||||||||||||||||||||
| Related Lupus Current Events and Lupus News Articles Saliva proteins change as women age In a step toward using human saliva to tell whether those stiff joints, memory lapses, and other telltale signs of aging are normal or red flags for disease, scientists are describing how the protein content of women's saliva change with advancing age. Smokers with common autoimmune disorder at higher risk for skin damage As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. Kidney transplants generally safe for lupus patients Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. Iberian wolves prefer wild roe deer to domestic animals A Spanish researcher has analysed the preferences of wolves from the north east of the Iberian Peninsula to demonstrate that, in reality, their favourite prey are roe deer, deer and wild boar, ahead of domestic ruminants (sheep, goats, cows and horses). OMRF scientists discover promising new path for treating traumas A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes. Lupus patients perceive benefit from cardiovascular disease prevention counseling program According to a new study by Hospital for Special Surgery investigators presented at the American College of Rheumatology meeting on October 21 in Philadelphia, most lupus patients are not aware that their condition puts them at a higher risk for cardiovascular disease and a counseling program is a valuable way to promote education and lifestyle change. Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease. National report shines light on lupus 50-year treatment drought Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration. Promising new target emerges for autoimmune diseases University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. McGill/JGH researchers successfully reverse multiple sclerosis in animals A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal. More Lupus Current Events and Lupus News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||